Get started
Author

Louise M. Walsh

Observed names: Louise M Walsh, Louise Walsh, Walsh, L.M.
ORCID: 0000-0003-4275-9501
Observed ORCID: 0000-0003-4275-9501
OpenAlex ID: A5033719084
Fragment-to-Lead Medicinal Chemistry Publications in 2020
2021 · Iwan J. P. de Esch, Daniel A. Erlanson, et al. · Journal of Medicinal Chemistry · 103
Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: A new use of silicon bioisosteres in medicinal chemistry
2006 · Matthew J. Barnes, Richard Conroy, et al. · Bioorganic & Medicinal Chemistry Letters · 67
Sulfide–BF3·OEt2 mediated Baylis–Hillman reactions
2002 · Louise M. Walsh, Caroline L. Winn, et al. · Tetrahedron Letters · 53
Fragment-to-Lead Medicinal Chemistry Publications in 2021
2023 · Louise Walsh, Daniel A. Erlanson, et al. · Journal of Medicinal Chemistry · 45
Assessment of the Target Engagement and d-Serine Biomarker Profiles of the d-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756
2017 · Eimear Howley, Michael Bestwick, et al. · Neurochemical Research · 30
A Fragment-Based Approach to IdentifyingS-Adenosyl- l -methionine -Competitive Inhibitors of CatecholO-Methyl Transferase (COMT).
2014 · Marion Lanier, Geza Ambrus, et al. · Journal of Medicinal Chemistry · 13
Stereochemical elucidation of the 1,4 polyketide amphidinoketide I
2003 · Louise M Walsh, Jonathan M Goodman · Chemical Communications · 13
Large-scale synthesis of 1,1,3,3,6-pentamethyl-1,3-disilaindan-5-ol via a CoBr2/Zn-catalyzed [2+2+2] cycloaddition reaction
2010 · Ryo Mizojiri, Richard Conroy, et al. · Tetrahedron · 9
Abstract 1627: Switching cell fate from senescence to apoptosis by the combination of a p53 corrector with the MDM2 antagonist ASTX295
2025 · George Ward, Judit Espana-Agusti, et al. · Cancer Research
Data from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S1 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Supplementary Figure Legends from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S2 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S3 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S2 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S3 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S4 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Data from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Supplementary Figure Legends from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S4 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Figure S1 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
2023 · Bo Li, Triona Ni Chonghaile, et al.
Works count: 53
Citation count: 333
H-index: 8
I10-index: 7
Year
Topic
Type